dyadic international inc - DYAI
DYAI
Close Chg Chg %
0.52 -0.01 -1.19%
Pre-Market
0.51
-0.01 (1.19%)
Volume: 57.69K
Last Updated:
Sep 9, 2026, 4:00 PM EDT
Company Overview: dyadic international inc - DYAI
DYAI Key Data
| Open $0.53 | Day Range 0.50 - 0.53 |
| 52 Week Range 0.48 - 1.60 | Market Cap $20.83M |
| Shares Outstanding 40.06M | Public Float 29.92M |
| Beta 0.96 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.21 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 186.31K |
DYAI Performance
| 1 Week | -1.21% | ||
| 1 Month | -33.70% | ||
| 3 Months | -24.65% | ||
| 1 Year | -46.85% | ||
| 5 Years | -91.03% |
DYAI Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
1
Full Ratings ➔
About dyadic international inc - DYAI
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.
DYAI At a Glance
Dyadic International, Inc.
1044 North US Highway One
Jupiter, Florida 33477-5094
| Phone | 1-561-743-8333 | Revenue | 3.09M | |
| Industry | Medical/Nursing Services | Net Income | -7,364,628.00 | |
| Sector | Health Services | Employees | 5 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
DYAI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.923 |
| Price to Book Ratio | 27.598 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.803 |
| Enterprise Value to Sales | 8.794 |
| Total Debt to Enterprise Value | 0.186 |
DYAI Efficiency
| Revenue/Employee | 618,069.00 |
| Income Per Employee | -1,472,925.60 |
| Receivables Turnover | 2.746 |
| Total Asset Turnover | 0.311 |
DYAI Liquidity
| Current Ratio | 2.684 |
| Quick Ratio | 2.684 |
| Cash Ratio | 2.319 |
DYAI Profitability
| Gross Margin | 24.932 |
| Operating Margin | -231.234 |
| Pretax Margin | -238.311 |
| Net Margin | -238.311 |
| Return on Assets | -74.106 |
| Return on Equity | -397.798 |
| Return on Total Capital | -117.027 |
| Return on Invested Capital | -107.194 |
DYAI Capital Structure
| Total Debt to Total Equity | 410.632 |
| Total Debt to Total Capital | 80.416 |
| Total Debt to Total Assets | 50.883 |
| Long-Term Debt to Equity | 407.822 |
| Long-Term Debt to Total Capital | 79.866 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Dyadic International Inc - DYAI
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 2.93M | 2.90M | 3.50M | 3.09M | |
Sales Growth
| +21.90% | -1.07% | +20.58% | -11.59% | |
Cost of Goods Sold (COGS) incl D&A
| 2.12M | 1.98M | 1.19M | 2.32M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | - | - | - | - |
Depreciation
| - | - | - | - | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +9.19% | -6.94% | -39.54% | +94.19% | |
Gross Income
| 807.11K | 922.96K | 2.30M | 770.49K | |
Gross Income Growth
| +75.69% | +14.35% | +149.28% | -66.51% | |
Gross Profit Margin
| +27.54% | +31.84% | +65.82% | +24.93% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 10.92M | 9.11M | 8.18M | 7.92M | |
Research & Development
| 4.50M | 3.30M | 2.04M | 2.15M | |
Other SG&A
| 6.42M | 5.82M | 6.13M | 5.76M | |
SGA Growth
| -27.62% | -16.56% | -10.26% | -3.21% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | (250.00K) | - |
EBIT after Unusual Expense
| (9.87M) | (8.19M) | (5.88M) | (7.15M) | |
Non Operating Income/Expense
| 130.50K | 1.40M | 497.07K | 237.19K | |
Non-Operating Interest Income
| 180.42K | 416.69K | 456.99K | 284.08K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 427.97K | 455.90K | - |
Interest Expense Growth
| - | - | - | +6.53% | - |
Gross Interest Expense
| - | - | 427.97K | 455.90K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (9.74M) | (6.80M) | (5.81M) | (7.36M) | |
Pretax Income Growth
| +25.52% | +30.20% | +14.51% | -26.78% | |
Pretax Margin
| -332.23% | -234.42% | -166.19% | -238.31% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (9.74M) | (6.80M) | (5.81M) | (7.36M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (9.74M) | (6.80M) | (5.81M) | (7.36M) | |
Net Income Growth
| +25.52% | +30.20% | +14.51% | -26.78% | |
Net Margin Growth
| -332.23% | -234.42% | -166.19% | -238.31% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (9.74M) | (6.80M) | (5.81M) | (7.36M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (9.74M) | (6.80M) | (5.81M) | (7.36M) | |
EPS (Basic)
| -0.3432 | -0.236 | -0.1981 | -0.2257 | |
EPS (Basic) Growth
| +26.90% | +31.24% | +16.06% | -13.93% | |
Basic Shares Outstanding
| 28.36M | 28.80M | 29.32M | 32.62M | |
EPS (Diluted)
| -0.3432 | -0.236 | -0.1981 | -0.2257 | |
EPS (Diluted) Growth
| +26.90% | +31.24% | +16.06% | -13.93% | |
Diluted Shares Outstanding
| 28.36M | 28.80M | 29.32M | 32.62M | |
EBITDA
| (10.12M) | (8.19M) | (5.88M) | (7.15M) | |
EBITDA Growth
| +30.86% | +19.02% | +28.24% | -21.57% | |
EBITDA Margin
| -345.21% | -282.58% | -168.17% | -231.23% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 6.00 | |
| Number of Ratings | 1 | Current Quarters Estimate | -0.045 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | -0.14 | |
| Last Quarter’s Earnings | -0.06 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.23 | Next Fiscal Year Estimate | 0.03 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 2 | 2 | 2 | 2 |
| Mean Estimate | -0.05 | 0.01 | -0.14 | 0.03 |
| High Estimates | -0.03 | 0.04 | -0.13 | 0.14 |
| Low Estimate | -0.06 | -0.02 | -0.15 | -0.08 |
| Coefficient of Variance | -47.14 | 424.26 | -10.10 | 518.54 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 1 | 1 | 1 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Dyadic International Inc - DYAI
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Dyadic International Inc - DYAI
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 8, 2026 | Seth J. Herbst Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | Ping W. Rawson Chief Financial Officer | 47,250 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Ping W. Rawson Chief Financial Officer | 170,151 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Joseph P. Hazelton President & COO | 67,250 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Joseph P. Hazelton President & COO | 191,758 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Ronen Tchelet VP of Research and Bus. Dvlpmt | 47,250 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Ronen Tchelet VP of Research and Bus. Dvlpmt | 50,897 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Seth J. Herbst Director | 39,894 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Seth J. Herbst Director | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Jack L. Kaye Director | 81,201 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | Seth J. Herbst Director | 202,311 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | Patrick K. Lucy Director | 39,894 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Patrick K. Lucy Director | 67,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Patrick K. Lucy Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | Patrick K. Lucy Director | 72,311 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | Jack L. Kaye Director | 39,894 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Jack L. Kaye Director | 67,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Jack L. Kaye Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |